<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="decrease">
            <roleset id="decrease.01" name="make smaller&#x0A;" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing decreased&#x0A;" />
                    <role n="2" descr="location&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and glucose consumption have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and glucose consumption were significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA has significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA is observed to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA was observed to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption are significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption can be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption can have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption could be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is able to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is believed to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption is shown to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption may be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption may have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption might be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption was able to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption was believed to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption was shown to be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption will be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption will have been significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and glucose consumption would be significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA can have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA can significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA could significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is able to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is believed to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is believed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is observed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is shown to have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is shown to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA may have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA may significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA might significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA significantly decreases glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA was able to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA was believed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA was shown to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA will significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA would significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA will have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Disruption of narL can decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Disruption of narL can have decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Disruption of narL could decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Disruption of narL decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Disruption of narL has decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Disruption of narL has the ability to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Disruption of narL is able to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Disruption of narL is believed to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Disruption of narL is shown to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Disruption of narL may decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Disruption of narL may have decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Disruption of narL might decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Disruption of narL was able to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Disruption of narL was believed to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Disruption of narL was shown to decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Disruption of narL will decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Disruption of narL will have decreased nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Disruption of narL would decrease nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection can be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection can have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection could be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection had been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is able to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is believed to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is shown to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection may be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection may have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection might be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was able to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was believed to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was shown to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection will be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection will have been decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection would be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and methionine content can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and methionine content can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and methionine content is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and methionine content is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and methionine content may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and methionine content may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and methionine content has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and methionine content could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and methionine content might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and methionine content was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and methionine content was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and methionine content will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and methionine content will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and methionine content would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Lipid peroxide synthesis can be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Lipid peroxide synthesis can have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Lipid peroxide synthesis could be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Lipid peroxide synthesis has been decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Lipid peroxide synthesis is able to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Lipid peroxide synthesis is believed to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Lipid peroxide synthesis is decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Lipid peroxide synthesis is shown to be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Lipid peroxide synthesis may be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Lipid peroxide synthesis may have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Lipid peroxide synthesis might be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Lipid peroxide synthesis was able to be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Lipid peroxide synthesis was believed to be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Lipid peroxide synthesis was decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Lipid peroxide synthesis was shown to be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Lipid peroxide synthesis will be decreased by treatment with melatonin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Lipid peroxide synthesis will have been decreased by treatment with melatonin, and have permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Lipid peroxide synthesis would be decreased by treatment with melatonin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity can be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity could be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity has been decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity is able to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity is believed to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity is decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity may be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity might be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was able to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was believed to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity will be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity would be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation can decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation could decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation decreases promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation had the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation has the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation is able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation is believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation may decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation might decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation was able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation was believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation will decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation would decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Nitrite induction of the nirB promoter can be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Nitrite induction of the nirB promoter can have been decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Nitrite induction of the nirB promoter could be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Nitrite induction of the nirB promoter has been decreased by disruption of narL which has not been suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Nitrite induction of the nirB promoter is able to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Nitrite induction of the nirB promoter is believed to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Nitrite induction of the nirB promoter is decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Nitrite induction of the nirB promoter is shown to be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Nitrite induction of the nirB promoter may be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Nitrite induction of the nirB promoter may have been decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Nitrite induction of the nirB promoter might be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Nitrite induction of the nirB promoter was able to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Nitrite induction of the nirB promoter was believed to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Nitrite induction of the nirB promoter was decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Nitrite induction of the nirB promoter was shown to be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Nitrite induction of the nirB promoter will be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Nitrite induction of the nirB promoter will have been decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Nitrite induction of the nirB promoter would be decreased by disruption of narL which was not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>The levels of Clara cell secretory protein can be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>The levels of Clara cell secretory protein can be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>The levels of Clara cell secretory protein can have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>The levels of Clara cell secretory protein could be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>The levels of Clara cell secretory protein could be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>The levels of Clara cell secretory protein has been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>The levels of Clara cell secretory protein is able to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>The levels of Clara cell secretory protein is able to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>The levels of Clara cell secretory protein is believed to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>The levels of Clara cell secretory protein is believed to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>The levels of Clara cell secretory protein is decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>The levels of Clara cell secretory protein is shown to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>The levels of Clara cell secretory protein is shown to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>The levels of Clara cell secretory protein may be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>The levels of Clara cell secretory protein may have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>The levels of Clara cell secretory protein might be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>The levels of Clara cell secretory protein might be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>The levels of Clara cell secretory protein was able to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>The levels of Clara cell secretory protein was believed to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>The levels of Clara cell secretory protein was decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>The levels of Clara cell secretory protein was shown to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>The levels of Clara cell secretory protein will be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>The levels of Clara cell secretory protein will be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>The levels of Clara cell secretory protein will have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>The levels of Clara cell secretory protein would be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>The levels of Clara cell secretory protein would be decreased in NLF from smokers, and it was also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>The production of C51 microcin can decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>The production of C51 microcin could decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>The production of C51 microcin decreases or is absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>The production of C51 microcin had the ability to to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>The production of C51 microcin has decreased or been absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>The production of C51 microcin has the ability to to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>The production of C51 microcin is able to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>The production of C51 microcin is believed to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>The production of C51 microcin is shown to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>The production of C51 microcin may decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>The production of C51 microcin might decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>The production of C51 microcin was able to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>The production of C51 microcin was believed to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>The production of C51 microcin was shown to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>The production of C51 microcin will decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>The production of C51 microcin would decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>Treatment with melatonin can decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>Treatment with melatonin could decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>Treatment with melatonin decreases lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>Treatment with melatonin has decreased lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>Treatment with melatonin is able to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>Treatment with melatonin is believed to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>Treatment with melatonin is shown to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>Treatment with melatonin may decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>Treatment with melatonin might decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>Treatment with melatonin was able to decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>Treatment with melatonin was believed to decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>Treatment with melatonin will decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>Treatment with melatonin would decrease lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli can be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli can have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli could be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli has been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is able to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is believed to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli is shown to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli may be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli may have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli might be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was able to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was believed to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was shown to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli will be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli will have been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli would be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>marA locus can decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>marA locus can have decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>marA locus could decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>marA locus decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>marA locus decreases expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>marA locus has decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>marA locus has the ability to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>marA locus is able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>marA locus is believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>marA locus is shown to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>marA locus may decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>marA locus may have decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>marA locus might decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>marA locus was able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>marA locus was believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>marA locus was shown to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>marA locus will decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>marA locus will have decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>marA locus would decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with lower expression levels and decreased methionine content), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>levels of Clara cell have been reported in several cardiac promoters and their mutation was shown to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="GREC" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="GREC" no="2">
                    <text>Disruption of narL decreases nitrite induction of the nirB promoter whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="GREC" no="3">
                    <text>The production of C51 microcin decreased or was absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="GREC" no="4">
                    <text>marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>It was found that NLF from smokers contained decreased levels of Clara cell secretory protein, and increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>Treatment with melatonin decreased lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL has significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL is observed to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL was observed to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin has significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin is observed to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin was observed to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and expression of OmpF porin have been significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and expression of OmpF porin were significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis were significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and marA locus has significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and marA locus is observed to have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and marA locus significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and marA locus was observed to have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter were significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and promoter activity have been significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and promoter activity were significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and their mutation has significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and their mutation is observed to have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and their mutation significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and their mutation was observed to have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL can have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL can significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL could significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is able to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is believed to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is believed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is observed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is shown to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is shown to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL may have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL may significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL might significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL significantly decreases nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL was able to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL was believed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL was shown to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL will significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL would significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin can have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin can significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin could significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is able to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is believed to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is believed to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is observed to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is shown to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin may have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin may significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin might significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin significantly decreases lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was able to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was believed to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin will significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin would significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin are significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin can be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin can have been significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin could be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin is able to be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin is believed to be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin is shown to be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin may be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin may have been significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin might be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin was able to be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin was believed to be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin was shown to be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin will be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin will have been significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin would be significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis are significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis can be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis can have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis could be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is believed to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is shown to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis may be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis may have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis might be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was believed to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was shown to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis will be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis will have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis would be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus can have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus can significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus could significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is able to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is believed to have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is believed to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is observed to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is shown to have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is shown to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus may have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus may significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus might significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus significantly decreases expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus was able to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus was believed to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus was shown to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus will significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus would significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter are significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter can be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter can have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter could be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter is able to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter is believed to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter is shown to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter may be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter may have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter might be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was able to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was believed to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was shown to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter will be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter will have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter would be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity are significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity can be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity can have been significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity could be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity is able to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity is believed to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity is shown to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity may be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity may have been significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity might be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity was able to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity was believed to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity was shown to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity will be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity will have been significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity would be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation can have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation can significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation could significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation is able to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation is believed to have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation is believed to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation is observed to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation is shown to have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation is shown to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation may have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation may significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation might significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation significantly decreases promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation was able to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation was believed to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation was shown to significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation will significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and their mutation would significantly decrease promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and Disruption of narL will have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin will have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and marA locus will have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and their mutation will have significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Disruption of narL can decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Disruption of narL could decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Disruption of narL decreased nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Disruption of narL decreases nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Disruption of narL has decreased nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Disruption of narL is able to decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Disruption of narL is believed to decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Disruption of narL is shown to decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Disruption of narL may decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Disruption of narL might decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Disruption of narL was able to decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Disruption of narL was believed to decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Disruption of narL will decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Disruption of narL would decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, The production of C51 microcin was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, marA locus would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">marA locus</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, methionine content was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation can be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation may have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation was being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation was believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation will be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, their mutation would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">their mutation</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and The production of C51 microcin can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and the RELN mRNA content can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and The production of C51 microcin can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and the RELN mRNA content can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and The production of C51 microcin is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and the RELN mRNA content is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and The production of C51 microcin is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and the RELN mRNA content is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and The production of C51 microcin may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and the RELN mRNA content may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and The production of C51 microcin may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and the RELN mRNA content may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and The production of C51 microcin has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and the RELN mRNA content has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and The production of C51 microcin could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and the RELN mRNA content could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and The production of C51 microcin might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and the RELN mRNA content might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and The production of C51 microcin was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and the RELN mRNA content was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and The production of C51 microcin was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and the RELN mRNA content was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and The production of C51 microcin will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and the RELN mRNA content will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and The production of C51 microcin will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the RELN mRNA content will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and The production of C51 microcin would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and the RELN mRNA content would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin can be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin could be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin has been decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin is able to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin is believed to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin is decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin may be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin might be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was able to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was believed to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin will be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin would be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus can decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus could decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus decreases expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus had the ability to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus has the ability to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus is able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus is believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus may decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus might decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus was able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus was believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus will decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus would decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>Treatment with melatonin can decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>Treatment with melatonin can have decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>Treatment with melatonin could decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>Treatment with melatonin decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>Treatment with melatonin decreases lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>Treatment with melatonin has decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Treatment with melatonin has the ability to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Treatment with melatonin is able to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Treatment with melatonin is believed to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Treatment with melatonin is shown to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Treatment with melatonin may decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Treatment with melatonin may have decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Treatment with melatonin might decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Treatment with melatonin was able to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Treatment with melatonin was believed to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Treatment with melatonin was shown to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Treatment with melatonin will decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Treatment with melatonin will have decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Treatment with melatonin would decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>levels of Clara cell have been reported in several cardiac promoters and marA locus was shown to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>marA locus can decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>marA locus can decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>marA locus can have decreased expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>marA locus could decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>marA locus could decrease expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>marA locus decreased expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>marA locus decreased expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>marA locus decreases expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>marA locus decreases expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>marA locus has decreased expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>marA locus has decreased expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>marA locus has the ability to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>marA locus is able to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>marA locus is able to decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>marA locus is believed to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>marA locus is believed to decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>marA locus is shown to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>marA locus is shown to decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>marA locus may decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>marA locus may decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>marA locus may have decreased expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>marA locus might decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>marA locus might decrease expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>marA locus was able to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>marA locus was able to decrease expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>marA locus was believed to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>marA locus was believed to decrease expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>marA locus was shown to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>marA locus will decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>marA locus will decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>marA locus will have decreased expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>marA locus would decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>marA locus would decrease expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>overexpression of ArcA can decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>overexpression of ArcA can decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>overexpression of ArcA can have decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>overexpression of ArcA could decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>overexpression of ArcA could decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>overexpression of ArcA decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>overexpression of ArcA decreased glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>overexpression of ArcA decreases glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>overexpression of ArcA decreases glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>overexpression of ArcA has decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>overexpression of ArcA has decreased glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>overexpression of ArcA has the ability to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>overexpression of ArcA is able to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>overexpression of ArcA is able to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>overexpression of ArcA is believed to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>overexpression of ArcA is believed to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>overexpression of ArcA is shown to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>overexpression of ArcA is shown to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>overexpression of ArcA may decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>overexpression of ArcA may decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>overexpression of ArcA may have decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>overexpression of ArcA might decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>overexpression of ArcA might decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>overexpression of ArcA was able to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>overexpression of ArcA was able to decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>overexpression of ArcA was believed to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>overexpression of ArcA was believed to decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>overexpression of ArcA was shown to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>overexpression of ArcA will decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>overexpression of ArcA will decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>overexpression of ArcA will have decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>overexpression of ArcA would decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>overexpression of ArcA would decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>promoter activity in cardiomyocytes can be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>promoter activity in cardiomyocytes can have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>promoter activity in cardiomyocytes could be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>promoter activity in cardiomyocytes has been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>promoter activity in cardiomyocytes is able to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>promoter activity in cardiomyocytes is believed to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>promoter activity in cardiomyocytes is decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>promoter activity in cardiomyocytes is shown to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>promoter activity in cardiomyocytes may be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>promoter activity in cardiomyocytes may have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>promoter activity in cardiomyocytes might be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>promoter activity in cardiomyocytes was able to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>promoter activity in cardiomyocytes was believed to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>promoter activity in cardiomyocytes was decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>promoter activity in cardiomyocytes was shown to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>promoter activity in cardiomyocytes will be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>promoter activity in cardiomyocytes will have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>promoter activity in cardiomyocytes would be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>their mutation can decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>their mutation can decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>their mutation can decrease promoter activity, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>their mutation can have decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>their mutation can have decreased promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>their mutation causes decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>their mutation could decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>their mutation could decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>their mutation could decrease promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>their mutation decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>their mutation decreased promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>their mutation decreased promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>their mutation decreases promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>their mutation decreases promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>their mutation decreases promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>their mutation has decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>their mutation has decreased promoter activity whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>their mutation has decreased promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>their mutation has the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>their mutation has the ability to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>their mutation is able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>their mutation is able to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>their mutation is able to decrease promoter activity, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>their mutation is believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>their mutation is believed to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>their mutation is believed to decrease promoter activity, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>their mutation is shown to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>their mutation is shown to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>their mutation is shown to decrease promoter activity, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>their mutation may decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>their mutation may decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>their mutation may decrease promoter activity, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>their mutation may have decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>their mutation may have decreased promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>their mutation might decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>their mutation might decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>their mutation might decrease promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>their mutation was able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>their mutation was able to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>their mutation was able to decrease promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>their mutation was believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>their mutation was believed to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>their mutation was believed to decrease promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>their mutation was shown to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>their mutation was shown to decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>their mutation will decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>their mutation will decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>their mutation will decrease promoter activity, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>their mutation will have decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>their mutation will have decreased promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>their mutation would decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>their mutation would decrease promoter activity whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>their mutation would decrease promoter activity, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PNAS" no="1">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, levels of Clara cell secretory protein was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the protection was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and levels of Clara cell secretory protein can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and the protection can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and levels of Clara cell secretory protein can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and the protection can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and levels of Clara cell secretory protein is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and the protection is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and levels of Clara cell secretory protein is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and the protection is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and levels of Clara cell secretory protein may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and the protection may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and levels of Clara cell secretory protein may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and the protection may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and levels of Clara cell secretory protein has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and the protection has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and levels of Clara cell secretory protein could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and the protection could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and levels of Clara cell secretory protein might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and the protection might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and levels of Clara cell secretory protein was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and the protection was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and levels of Clara cell secretory protein was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and the protection was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and levels of Clara cell secretory protein will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and the protection will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and levels of Clara cell secretory protein will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the protection will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and levels of Clara cell secretory protein would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and the protection would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
